Literature DB >> 24802278

Management of bone metastases in patients with castration-resistant prostate cancer.

Richard Cathomas1, Zoltan Bajory, Mounira Bouzid, Ahmed El Ghoneimy, Silke Gillessen, Frederico Goncalves, Gabriel Kacso, Gero Kramer, Piotr Milecki, Dalibor Pacik, Wahid Tantawy, Krzystof Lesniewski-Kmak.   

Abstract

Bone metastases are a very common problem in prostate cancer. They are associated with considerable morbidity, adversely affect quality of life and frequently lead to advanced bone events (so-called skeletal-related events, SREs); SREs include fractures, spinal cord compression and the requirement for bone surgery or bone radiation. The aim of this paper was to evaluate currently available treatment options in the prevention and management of SREs and bone metastases in men with castration-resistant prostate cancer and to outline the importance of interdisciplinary management strategies. It also discusses the diagnostic workup of osseous metastases and practical considerations for the utilization of bone-targeted therapies in accordance with current guidelines to provide a consensus for special and/or difficult clinical situations.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24802278     DOI: 10.1159/000358258

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  7 in total

1.  Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant Etiologies.

Authors:  Lisa Marie Ruppert; Erica Dayan Cohn; Niamh M Keegan; Abigail Bacharach; Sungmin Woo; Theresa Gillis; Howard I Scher
Journal:  JCO Oncol Pract       Date:  2022-02-17

2.  Management of cancer pain with analgetic adjuvant and weak opioid in prostate cancer bone metastases: A case series.

Authors:  Jufriady Ismy; Dessy Rakhmawati Emril
Journal:  Ann Med Surg (Lond)       Date:  2020-11-09

Review 3.  Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence.

Authors:  Fred Saad; Frédéric Pouliot; Brita Danielson; Charles Catton; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2018-05-14       Impact factor: 1.862

4.  Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials.

Authors:  F Saad; C Ivanescu; D Phung; Y Loriot; S Abhyankar; T M Beer; B Tombal; S Holmstrom
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-01-03       Impact factor: 5.554

Review 5.  Three-Dimensional Cell Cultures as an In Vitro Tool for Prostate Cancer Modeling and Drug Discovery.

Authors:  Fabrizio Fontana; Michela Raimondi; Monica Marzagalli; Michele Sommariva; Nicoletta Gagliano; Patrizia Limonta
Journal:  Int J Mol Sci       Date:  2020-09-16       Impact factor: 5.923

Review 6.  The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer.

Authors:  Diomidis Kozyrakis; Dionyssios Paridis; Stefanos Perikleous; Konstantinos Malizos; Anastasios Zarkadas; Antonios Tsagkalis
Journal:  Adv Urol       Date:  2018-12-26

Review 7.  Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets.

Authors:  Fabrizio Fontana; Michela Raimondi; Monica Marzagalli; Alessandro Di Domizio; Patrizia Limonta
Journal:  Cells       Date:  2020-02-18       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.